تداول رهيب بعد تحديد هدف سعري خلال سنة بين 3 الى 3.5 ..... اعتقد انها سوف تصل الى اكثر وذلك لمستقبل الشركة المشجع Torc Investments and Research Initiates Coverage of Generex Biotechnology With a Buy Rating and 12-Month Price Target of $3.00-$3.50 Wednesday September 27, 9:35 am ET TORONTO--(MARKET WIRE)--Sep 27, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News) announced today that Torc Investments and Research LLC, a NASD registered broker-dealer, initiated research coverage of the Company today with a Buy rating and a 12-month price target of $3-$3.50. ADVERTISEMENT The Report, issued by Director of Research Amanda McNamara, noted that, "The company's main product is centered on diabetes, a very lucrative and growing market where it is estimated that 350 million people worldwide will be affected by 2025 (up from 230 million currently). According to the International Diabetes Federation, every 10 seconds a person dies from diabetes-related causes where it is the fourth leading cause of death by disease globally. Many of these complications can be avoided if the disease is treated early on and diabetics were more compliant in treating their disease. As more user-friendly delivery devices for insulin enter the marketplace to replace needles, compliance should increase significantly. But such alternative delivery methods for insulin have their own setbacks...A very viable solution to such issues rests with insulin mouth sprays where insulin is delivered through the mouth and avoids the lungs." The Report noted that, "Generex Oral-lyn is a mouth spray that allows for incremental dosing and comes in a convenient pump similar in size to a common asthma pump versus competitive inhaled insulin products that are bulky. This product is available for sale in Ecuador, a key introductory market to build momentum and brand awareness despite its small size...Although Generex has multiple products in its pipeline, the true driver of sales will stem from the success of Generex Oral-lyn. Highlighting this fact for valuation purposes, we are comparing and discounting Generex's market capitalization to MannKind Corp. since both companies target the alternative insulin delivery market and both are reliant on one main product to significantly drive sales." The Report concluded that, "We believe a fair price target range for Generex Biotechnology Corporation over the next 12 months is $3.00 to $3.50, equating the market capitalization of GNBT to $330 million - $385 million (using an estimated average number of shares outstanding of 110 million for fiscal 2007 for GNBT). This range is less than half of MannKind's current market capitalization of $921 million but is not unreasonable due to the comparison of targeted markets. MannKind's product (Technosphere Insulin), although roughly 3 1/2 years away from possibly receiving FDA approval, targets the U.S. market that consists of approximately 23 million diabetics (20-79 age group) versus Generex's current targeted markets for Generex Oral-lyn (Mexico, Canada and Andean countries) that have approximately 18.6 million diabetics combined (same age group). Valuations applied to Generex also recognize the valuable work being done at the company's Antigen Express subsidiary as it moves forward into drug development and away from strictly working in the laboratory for various cancers." "We are pleased that an independent research firm has recognized the value of our portfolio of products," said Anna Gluskin, President and Chief Executive Officer of Generex Biotechnology. "We believe that there exists great potential for Oral-lyn and look forward to further demonstrating our unique ability to orally deliver insulin through additional clinical activities and by entering new markets."